1-UFT protocol

chemotherapy protocol consisting of above two cpds in molar ratio of 1 for FT & 4 for uracil; do not confuse with the drug combination UFT (=UFTR drug)

Also Known As:

Networked: 10 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Iijima, Shohei: 1 article (11/2016)
2.	Nishioka, Kiyonori: 1 article (11/2016)
3.	Oshima, Satoshi: 1 article (11/2016)
4.	Takachi, Ko: 1 article (11/2016)
5.	Takemoto, Hiroyoshi: 1 article (11/2016)
6.	Tsujimura, Naoto: 1 article (11/2016)
7.	Uemura, Yoshio: 1 article (11/2016)
8.	Bendell, Johanna C: 1 article (03/2008)
9.	Cohen, Darrel P: 1 article (03/2008)
10.	Czito, Brian G: 1 article (03/2008)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 07/01/1999 - "A prospective, randomized clinical trial was conducted to evaluate the efficacy of endocrine chemotherapy with uracil and tegafur (in a molar ratio of 4:1 [UFT]) in patients with prostate cancer. "
2.	Colorectal Neoplasms (Colorectal Cancer) 07/01/1999 - "This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict chemosensitivity to postoperative fluoropyrimidines to prevent recurrence of disease. " 07/01/1999 - "Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) (N = 188) vs 5-fluorouracil (5-FU) plus oral calcium folinate (N = 185). "
3.	Breast Neoplasms (Breast Cancer) 07/01/1999 - "Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. " 07/01/1999 - "This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 07/01/1999 - "A phase I, single-center, open-label, dose-escalation study (University of Alabama [UAB] 9614) has been undertaken to evaluate the feasibility and safety of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) plus radiotherapy in patients with pancreatic cancer. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/01/1999 - "A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in patients with locally advanced non-small-cell lung cancer. "

Related Drugs and Biologics

1.	Uracil
2.	Tegafur
3.	Leucovorin (Folinic Acid)
4.	Paclitaxel (Taxol)
5.	Fluorouracil (Carac)
6.	Cisplatin (Platino)
7.	Carboplatin (JM8)
8.	Floxuridine (FUdR)
9.	pyrimidine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Ambulatory Care (Outpatient Care)
4.	Adjuvant Chemotherapy